Showing results (61-70 of 366) with videos related to

Sort By:
Pageof 37
Seminars in Oncology|February 26, 2004
Molecular predictors of response to chemotherapy in lung cancerRafael Rosell, Miquel Taron, Aurelio Ariza, et al.
Clinical Lung Cancer|April 12, 2015
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Lodovico Balducci, Fortunato Ciardiello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
Cancers|December 23, 2023
Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on ImmunotherapySusana Cedres, Augusto Valdivia, Patricia Iranzo, et al.
Targeted Oncology|September 9, 2014
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trialDavid F Heigener, José Rodrigues Pereira, Enriqueta Felip, et al.
Clinical Lung Cancer|April 23, 2005
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgeryEnriqueta Felip, Miquel Taron, Rafael Rosell, et al.
ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2024
A pragmatic guide for management of adverse events associated with lorlatinibGeoffrey Liu, Julien Mazieres, Jan Stratmann, et al.
Future Oncology (London, England)|April 8, 2026
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV studyAlessandra Bearz, Serena Ricciardi, Nirmal Vivek Raut, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 4, 2012
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)Pilar Garrido, Javier de Castro, Ángel Concha, et al.
Pageof 37